{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dawood S"],"funding":["NCI NIH HHS"],"pagination":["92-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2799236"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["PURPOSE The purpose of this study was to determine whether trastuzumab improves prognosis of women with metastatic human epidermal growth factor receptor 2 (HER2)/neu -positive breast cancer beyond that of women with HER2/neu-negative disease. PATIENTS AND METHODS Two thousand ninety-one women with metastatic breast cancer diagnosed from 1991 to 2007, with known HER2/neu status and who had not received trastuzumab in the adjuvant setting, were identified. Disease was classified into the following three groups: HER2/neu negative, HER2/neu positive without first-line trastuzumab treatment, and HER2/neu positive with first-line trastuzumab treatment. Overall survival (OS) was estimated using the Kaplan-Meier product-limit method and compared between groups with the log-rank test. Cox proporti"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review."],"pmcid":["PMC2799236"],"funding_grant_id":["1K07 CA109064-05","K07 CA109064"],"pubmed_authors":["Dawood S","Buzdar AU","Broglio K","Hortobagyi GN","Giordano SH"],"additional_accession":[]},"is_claimable":false,"name":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.","description":"PURPOSE The purpose of this study was to determine whether trastuzumab improves prognosis of women with metastatic human epidermal growth factor receptor 2 (HER2)/neu -positive breast cancer beyond that of women with HER2/neu-negative disease. PATIENTS AND METHODS Two thousand ninety-one women with metastatic breast cancer diagnosed from 1991 to 2007, with known HER2/neu status and who had not received trastuzumab in the adjuvant setting, were identified. Disease was classified into the following three groups: HER2/neu negative, HER2/neu positive without first-line trastuzumab treatment, and HER2/neu positive with first-line trastuzumab treatment. Overall survival (OS) was estimated using the Kaplan-Meier product-limit method and compared between groups with the log-rank test. Cox proporti","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Jan","modification":"2025-04-19T15:52:19.738Z","creation":"2019-03-27T00:27:39Z"},"accession":"S-EPMC2799236","cross_references":{"pubmed":["19933921"],"doi":["10.1200/jco.2008.19.9844","10.1200/JCO.2008.19.9844"]}}